Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS

Exclusion criteria

• ✕. Growth hormone deficiency (GHD) (confirmed by GH stimulation test);
• ✕. Turner syndrome (confirmed by karyotype test of girls);
• ✕. Noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with skin disease and congenital heart disease, missense mutation of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene on chromosome 12 for half of the participants, for both male and female participants);
• ✕. Laron syndrome (confirmed by IGF-1 generation test);
• ✕. Small for gestational age ( the birth height or weight is below the tenth percentile or 2 SD, with catch-up growth uncompleted at 2 years old);
• ✕. Growth disorders caused by malnutrition or hypothyroidism (thyroid function test).